Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment
| Autor: | M. Seitz, J.‐M. Dayer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_treatment Arthritis Inflammation Pharmacology Peripheral blood mononuclear cell Arthritis Rheumatoid Rheumatology medicine Humans Pharmacology (medical) Autoimmune disease Chemotherapy Tissue Inhibitor of Metalloproteinase-1 business.industry Interleukin-6 Middle Aged medicine.disease Methotrexate Rheumatoid arthritis Immunology Leukocytes Mononuclear Female medicine.symptom Matrix Metalloproteinase 1 business Ex vivo Immunosuppressive Agents medicine.drug |
| Popis: | Objective. To determine the effects of methotrexate (MTX ) treatment of rheumatoid arthritis (RA) patients (a) on the circulating levels and (b) on the ex vivo production of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinases-1 ( TIMP-1) by peripheral blood mononuclear cells (PBMNC ). Methods. Circulating levels, spontaneous ex vivo and in vitro production of MMP-1, TIMP-1 and interleukin-6 (IL-6) were assessed by immunoassays in sera and culture supernatants of PBMNC derived from 27 patients with active RA before and 3 months after beginning MTX treatment and from seven healthy subjects. The production and serum levels of MMP-1, TIMP-1 and IL-6 were correlated to the clinical response. Results. PBMNC of RA patients showing � 20% improvement of the Paulus index after 3 months of MTX treatment (responders; n = 16) exhibited a significantly enhanced production of spontaneous TIMP-1 ex vivo which was associated with the enhanced synthesis of IL-6. In contrast, PBMNC of 11 patients with |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|